Role of the studyof urinary molecular mediators of immune inflammationand renal fibrosis in chronic glomerulonephritis


Cite item

Full Text

References

  1. Segerer S., Nelson P. J., Schlondorff D. Chemokines, chemokine receptors and renal disease: from basic science to pathophysiologic and therapeutic studies. J. Am. Soc. Nephrol. 2000; 11: 152-176.
  2. Anders H. J., Vielhauer V., Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003; 63: 401-415.
  3. Wada Т., Yokoyama H., Kobayashi K. Chemokines: new target molecules in renal disease. Clin. Exp. Nephrol. 2000; 4: 273- 280.
  4. Козловская Л. В., Тареева И. Е., Мухин Н. А., Неверов Н. И. Мочевые тесты воспаления при гломерулонефрите. Тер. арх. 1994; 6: 11-15.
  5. Wada Т., Yokoyama H., Tomosugi N. et al. Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 1994; 46: 455-460.
  6. Yokoyama K, Wada T, Furuichi K. et al. Urinary levels chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J. Leukocyte Biol. 1998; 63: 493-499.
  7. Wada Т., Furuichi K, Segawa С et al. MlP-la and MCP-1 contribute crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int. 1999; 56: 995-1003.
  8. Grandaliano G., Gesualdo L., Ranieri G. et al. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: A pathogenic role in interstitial monocyte recruit-ment. J. Am. Soc. Nephrol. 1996; 7: 906-913.
  9. Zoja C, Donadelli R., Colleoni S. et al. Protein overload stimulates RANTES production by proxomal tubular cells depend ing on NF-kappaB activation. Kidney Int. 1998; 53: 1608- 1615.
  10. Guijarro C, Egido J. Transcription factor-kB (NF-kB) and renal disease. Kidney Int. 2001; 59: 415-424.
  11. Wada Т., Furuichi K, Sakai N. et al. A new anti-inflammatory compound FR 167653 ameliorates crescentic glomerulonephritis in KWY rats. J. Am. Soc. Nephrol. 2000; 11: 1534-1541.
  12. Wada Т., Tomosugi N.. Naito T. et al. Prevention of proteinuria by administration of anti-interleukin 8 antibody in experi- mental acute immune complex-induced glomerulonephritis. J. Exp. Med. 1994; 180: 1135-1140.
  13. Wada Т., Yokoyama H, Furuichi K. et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemo- -87 tactic and activating factor (MCAF/MCP-1). FASEB J. 1996; 10: 1418-1425.
  14. Chen S., Bacon К. В., Li L. et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenua- tion of glomerulonephritis in Wistar-Kyoto (WKY) rats byvMIP-II. J. Exp. Med. 1998; 188: 193-198.
  15. Kang D. H, Kanellis J., Hugo C. et al. Role of microvascular endothelium in progressive renal disease. J. Am. Soc. Neph- rol. 2002; 13: 806-816.
  16. Бобкова И. Н, Козловская Л. В., Полянцева Л. Р., ТарееваИ. Е. Клиническое значение определения фактора Виллебранда у больных волчаночным нефритом. Тер. арх. 1995; 5: 14-16.
  17. Козловская Л. В., Бобкова И. И., Щербак А. В., ПлиеваО. К. Клиническое значение определения в моче больных гломерулонефритом молекулярных медиаторов воспаления. Нефрология 2003; 7: 197-198.
  18. Бобкова И. Н., Полянцева Л. Р., Тареева И. Е. и др. Тест венозной окклюзии в оценке фибринолитической активности сосудистого эндотелия у больных волчаночным нефритом. Тер. арх. 1995; 4: 42-45.
  19. Rerolle J. P., Hertig A. et al. Plasminogen activator inhibitor I is a potential target in renal fibrogenesis. Kidney Int. 2000; 58: 1841-1850.
  20. Hamano K. et al. Expression of glomerular plasminogen activator inhibitor type I in glomerulonephritis. Am. J. Kidney Dis. 2002; 39 (4): 695-705
  21. Щербак А. В., Балкаров И. М., Козловская Л. В. и др. Снижение фибринолитической активности мочи у пациентов с наследственно обусловленным нарушением обмена мочевой кислоты. Тер. арх. 2001; 6: 8-10.
  22. Dennler H, Itoh S., Vivien D. et al. Direct binding of Smad 3 and Smad 4 to critical TGF-p-inducible elements in the promoter of human plasminogen activator inhibitor type-I gene.EMBO J. 1998; 17: 3091-3100.
  23. Sawa Y., Sobel B. E., Fum S. Inhibition of type-I plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscule cells. J. Biol. Chem. 1994; 269: 14149-14152.
  24. Ciemewski С S., Babinska A., Swiatkowska M. Inhibition by modified oligodeoxynucleotides of the expression of type-1 plasminogen activator inhibitor in human endothelial cells.Eur. J. Biochem. 1995; 227: 494-499.
  25. Козловская Л. В., Бобкова И. Н., Варшавский В. А. и др. Фибронектин мочи как показатель процессов фиброзирования в почке при нефрите. Тер. арх. 1999; 6: 34-38.
  26. Plieva О. К, Shvetsov М., Kozlovskaya L. et al. Nephroprotective and antifibrogenic effects of angiotensin receptor blocker valsartan in chronic glomerulonephritis patients. Nephrol. Di- al. Transplant. 2003; 18: 134.
  27. Remuzzi G., Bertani T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 1998; 339: 1448-1456.
  28. Meyer T. Tubular injury in glomerular disease. Kidney Int. 2003; 63: 774-787.
  29. Vliet V., Isolde E., Anita I. et al. Fibronectin accumulation in glomerulosclerotic lesions: Self-assembly sites and the heparin II binding domain. Kidney Int. 2002; 61: 481-489.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies